Alkermes plc. Marketable Securities, Unrealized Gain (Loss)
Alkermes plc. (ALKS) reported Marketable Securities, Unrealized Gain (Loss) of -$71.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-25.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2016-02-25
- Alkermes plc. marketable securities, unrealized gain (loss) for the quarter ending 2015-12-31 was -$611.00K.
- Alkermes plc. marketable securities, unrealized gain (loss) for the quarter ending 2015-09-30 was $60.00K.
- Alkermes plc. marketable securities, unrealized gain (loss) for the quarter ending 2015-06-30 was -$47.00K.
- Alkermes plc. marketable securities, unrealized gain (loss) for the quarter ending 2015-03-31 was $527.00K, a 97.01% decline year-over-year.
- Alkermes plc. marketable securities, unrealized gain (loss) for fiscal 2015 was -$71.00K, a 155.91% decline from fiscal 2014.
- Alkermes plc. marketable securities, unrealized gain (loss) for fiscal 2014 was $127.00K, a 99.41% decline from fiscal 2013.
- Alkermes plc. marketable securities, unrealized gain (loss) for fiscal 2013 was $21.41M.
- Alkermes plc. marketable securities, unrealized gain (loss) for fiscal 2013 was $64.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2015-12-31 | -$611.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$551.00K derived: sum of 2 quarters · filed 2016-02-25 | -$598.00K derived: sum of 3 quarters · filed 2016-02-25 | -$71.00K 10-K · filed 2016-02-25 | |
| 2015-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $13.00K derived: sum of 2 quarters · filed 2015-10-29 | $540.00K 10-Q · filed 2015-10-29 | ||
| 2015-06-30 | -$47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $480.00K 10-Q · filed 2015-07-30 | |||
| 2015-03-31 | $527.00K 10-Q · filed 2015-04-30 | ||||
| 2014-12-31 | $127.00K 10-K · filed 2016-02-25 | -$127.00K 10-K · filed 2015-02-24 | |||
| 2014-06-30 | -$17.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $382.00K 10-Q · filed 2014-07-31 | $13.60M derived: sum of 3 quarters · filed 2014-07-31 | ||
| 2014-03-31 | $17.63M 10-Q · filed 2014-04-30 | $30.84M derived: sum of 2 quarters · filed 2014-04-30 | |||
| 2013-12-31 | $13.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-04-30 | $21.41M 10-Q · filed 2014-04-30 | $21.41M 10-K · filed 2015-02-24 | ||
| 2013-09-30 | $8.19M 10-Q · filed 2013-10-31 | ||||
| 2013-03-31 | $64.00K 10-KT · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |